Skip to Main Content
Table 1

Comparison of clinical outcomes at baseline with outcomes assessed during the first 6 months of CGM use and during months 6–12 after CGM initiation

BaselineFollow-up 1 (months 2–6)PFollow-up 2 (months 6–12)P
HbA1c      
 % 7.58 (6.95, 8.23) 7.47 (6.89, 8.13) <0.0001 7.48 (6.91, 8.18) <0.0001 
 mmol/mol 59.3 (52.5, 66.5) 58.2 (51.8, 65.4)  58.2 (52.0, 65.9)  
 Percentage of subjects with HbA1c <7.5% (<58 mmol/mol) 47.1 52.3 <0.0001 50.5 <0.0001 
DKA      
 Percentage of subjects with at least 1 event 1.0 0.5 0.0055 0.5 0.0143 
 Event rate, events/100py (95% CI) 2.0 (1.4–2.9) 1.2 (0.7–1.9) 0.06 1.1 (0.7–1.7) 0.0254 
SH      
 Percentage of subjects with at least 1 event 3.4 1.8 <0.0001 2.6 0.0366 
 Event rate, events/100py (95% CI) 9.3 (7.3–11.8) 6.9 (5.1–9.5) 0.13 8.6 (6.4–11.4) 0.66 
SH with coma/convulsion      
 Percentage of subjects with at least 1 event 1.4 0.5 <0.0001 0.8 0.0153 
 Event rate, events/100py (95% CI) 2.5 (1.9–3.4) 1.2 (0.7–1.9) 0.0062 1.8 (1.2–2.6) 0.15 
BaselineFollow-up 1 (months 2–6)PFollow-up 2 (months 6–12)P
HbA1c      
 % 7.58 (6.95, 8.23) 7.47 (6.89, 8.13) <0.0001 7.48 (6.91, 8.18) <0.0001 
 mmol/mol 59.3 (52.5, 66.5) 58.2 (51.8, 65.4)  58.2 (52.0, 65.9)  
 Percentage of subjects with HbA1c <7.5% (<58 mmol/mol) 47.1 52.3 <0.0001 50.5 <0.0001 
DKA      
 Percentage of subjects with at least 1 event 1.0 0.5 0.0055 0.5 0.0143 
 Event rate, events/100py (95% CI) 2.0 (1.4–2.9) 1.2 (0.7–1.9) 0.06 1.1 (0.7–1.7) 0.0254 
SH      
 Percentage of subjects with at least 1 event 3.4 1.8 <0.0001 2.6 0.0366 
 Event rate, events/100py (95% CI) 9.3 (7.3–11.8) 6.9 (5.1–9.5) 0.13 8.6 (6.4–11.4) 0.66 
SH with coma/convulsion      
 Percentage of subjects with at least 1 event 1.4 0.5 <0.0001 0.8 0.0153 
 Event rate, events/100py (95% CI) 2.5 (1.9–3.4) 1.2 (0.7–1.9) 0.0062 1.8 (1.2–2.6) 0.15 

Data are median (interquartile range) unless otherwise indicated. Baseline, 6 months prior to CGM start; follow-up 1, outcomes assessed during the first 6 months of CGM use; follow-up 2, outcomes assessed during months 6–12 after CGM initiation (n = 3,553). McNemar test was used for dichotomous variables, and Wilcoxon signed rank test was used for continuous variables. Event rates were analyzed using a Poisson generalized estimation equation model. 100py, 100 person-years.

Close Modal

or Create an Account

Close Modal
Close Modal